1801 — Innovent Biologics Share News
0.000.00%
Last trade - 00:00- HK$150.85bn
- HK$130.09bn
- CNY13.04bn
China's medical products regulator approves Innovent Biologics's weight control injection
Brief: Innovent Biologics To Place 55 Million Placing Shares
Focus: China pharma projects disrupted by Sino-US tensions
Hutchmed Hits 2: month high on drug application for kidney cancer treatment
Brief: HUTCHMED (China) Says NDA Acceptance In China For Fruquintinib Combination With Sintilimab
Alphamab Oncology leads slide in HK pharma stocks on Trump's plan to trim medicine prices
Innovent Biologics rises on robust Q1 product revenue growth
Brief: Innovent Biologics Says Qtrly Achieved Total Product Revenue Exceeding RMB2.4 Billion
Brief: Innovent Biologics Says Third-Generation EGFR TKI Limertinib Received Approval From NMPA
Brief: Innovent Announces 2024 Annual Results And Business Updates
Brief: Hutchmed (China) Says Frusica-2 Phase II/III Study Met Primary Endpoint
Brief: Innovent Is Said To Consider Licensing Partnership For Cancer Drug- Bloomberg News
Brief: Innovent Biologics Says NMPA China Accepts New Drug Application For Ipilimumab Injection
Innovent Biologics rises as regulator approves co's product for cancer treatment
Brief: Innovent Biologics Says Third-Generation EGFR TKI Limertinib Received Approval By NMPA China
Innovent climbs as China regulator approves new drug application
Brief: Innovent Biologics Says Nmpa Approves Second New Drug Application Of Ros1 Inhibitor Dovbleron
Brief: Innovent Biologics Announces Entering Into Exclusive Global License Agreement
Brief: Innovent Biologics Says NMPA Approved New Drug Application Of Dovbleron